Health Trials

About this trial

NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab). In this study, investigators hypothesize that the combination of cabozantinib (a multi-kinase inhibitor) and atezolizumab will result in better therapeutic value.

Eligibility criteria

Qualifiers

Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent

Males and females age ≥ 18 years

ECOG Performance Status 0 - 1

Pathologically confirmed advanced/metastatic NSCLC, with PD-L1<1% based on IHC using 22C3 antibody

Disqualifiers

Simultaneously enrolled in any therapeutic clinical trial

Current or anticipating use of other investigational agents while participating in this study

Treatment with investigational therapy within 28 days prior to initiation of study treatment

Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements

Trial design

Treatments tested in this trial

  • Cabozantinib
  • Atezolizumab

Treatment groups

40 Participants
are divided into 1 treatment group

Locations

4
The University of Kansas Cancer Center - Westwood66205, Kansas CityKansas, United States
The University of Kansas Cancer Center - Indian Creek66211, Overland ParkKansas, United States
The University of Kansas Cancer Center - North64154, Kansas CityMissouri, United States
The University of Kansas Cancer Center - Lee's Summit64064, Lee's SummitMissouri, United States

Sponsors and collaborators

Jun Zhang, MD, PhD

Lead sponsor

University of Kansas Medical Center

Sponsor institution

Exelixis

Collaborator

Genentech, Inc.

Collaborator

Source ClinicalTrials.gov